The University of Texas MD Anderson Cancer Center and Summit Therapeutics, Inc. today announced a strategic five-year collaboration agreement for the purpose of accelerating the development of ivonescimab.
MD Anderson and Summit Therapeutics partner to accelerate ivonescimab development
- Post author:
- Post published:
- Post category:uncategorized